Pfizer Inc (PFE) Stock Price, Quote & News

Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands;...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 212 733 2323

Website: www.pfizer.com

Address:

66 Hudson Boulevard East, New York, United States

woolybully Jun. 29 at 7:03 PM

$ELTP $WEN $GME $PFE $JNJ

1 · Reply

morgangj Jun. 29 at 6:58 PM

$PFE

0 · Reply

_Crim_Jamer_ Jun. 29 at 6:58 PM

$PFE gap near 26.

1 · Reply

Micheal_Pothead Jun. 29 at 6:14 PM

$PFE the most Pfizer shit ever

0 · Reply

Micheal_Pothead Jun. 29 at 6:13 PM

$PFE lmfao it can’t ever hold any gains

0 · Reply

sethmarcus Jun. 29 at 5:25 PM

$VIX $SPY $AMZN $MU $PFE

0 · Reply

LoneBroker Jun. 29 at 5:21 PM

$PFE $24.29 🐻 • RSI 35.71 • ATR% 2.38 • vol↓ Support & Resistance — UPDATED 2026-06-26 3 Days | Support: $23.62 – $23.62 | Resistance: $25.11 – $25.11 5 Days | Support: $23.62 – $23.62 | Resistance: $25.31 – $25.31 7 Days | Support: $23.62 – $23.62 | Resistance: $26.28 – $26.28 20 Days | Support: $23.62 – $23.62 | Resistance: $26.49 – $26.49 60 Days | Support: $23.62 – $23.62 | Resistance: $28.75 – $28.75 100 Days | Support: $23.62 – $23.62 | Resistance: $28.75 – $28.75 200 Days | Support: $23.58 – $23.58 | Resistance: $28.75 – $28.75 Momentum leans bearish with RSI at 35.71. Volatility sits at 2.38% ATR, indicating contraction. Volume shows vol↓, signaling trader attention to recent flow. -------------------------- 📌 RSI = momentum (0–100). >50 = strength, <50 = weakness 📌 ATR% = daily volatility (higher = bigger swings) 📌 Legend: 🐂 bullish • 🐻 bearish • 😐 neutral • vol↑ rising volume • vol↓ easing volume ⏳ Valid until: 1:00 PM PT

0 · Reply

Micheal_Pothead Jun. 29 at 4:51 PM

$PFE hey LLY is green again :)

1 · Reply

PFElinepfrenzy1990 Jun. 29 at 4:50 PM

$PFE - Cursed Straße

0 · Reply

MrPeanutEsquire Jun. 29 at 4:44 PM

$PFE How about a little Pfizer trivia for our Monday. Over the last 5 years, what # do we rank on the s&p for performance?

3 · Reply

Pfizer, Innovent GLP-1 drugs pass China insurance preliminary review

Jun 24, 2026, 3:52 PM EDT - 4 days ago

Pfizer Declares Third-Quarter 2026 Dividend

2026-06-24T18:20:21.000Z - 5 days ago

Pfizer confirms FDA approval of Ibrance for HR+ metastatic breast cancer

Jun 24, 2026, 2:10 PM EDT - 5 days ago

FDA Approves Pfizer's IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance

2026-06-24T15:25:12.000Z - 5 days ago

FDA approves Pfizer’s Ibrance combo for metastatic breast cancer

Jun 24, 2026, 10:51 AM EDT - 5 days ago

Pfizer dismissed from US states' drug price-fixing lawsuit

Jun 23, 2026, 12:10 PM EDT - 6 days ago

China outpacing Europe in drug innovation and development, Pfizer executive says

Jun 23, 2026, 10:00 AM EDT - 6 days ago

Pfizer Invites Public to View and Listen to Webcast of August 4 Conference Call with Analysts

Jun 22, 2026, 4:43 PM EDT - 6 days ago

Pfizer's experimental drug misses main goal of lung cancer trial

2026-06-22T20:33:17.000Z - 6 days ago

Pfizer says sigvotatug vedotin did not show big improvement in primary endpoint

Jun 22, 2026, 4:30 PM EDT - 6 days ago

Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer

Jun 22, 2026, 2:32 PM EDT - 7 days ago

Wall Street loves growth stocks — but these 10 ‘losers' are primed to win

ACHR AGCO COF DHI DVN EOG TSN

2026-06-18T18:35:11.000Z - 11 days ago

Pfizer (PFE) Shares Sink After Surprise CFO Exit

2026-06-18T17:30:31.000Z - 11 days ago

Pfizer reaffirms all components of FY26 guidance

2026-06-18T10:52:33.000Z - 11 days ago

Pfizer CFO Dave Denton to step down, Cecile Guegan named interim CFO

Jun 18, 2026, 6:52 AM EDT - 11 days ago

Pfizer CFO Dave Denton to step down, leave company in August

Jun 18, 2026, 6:45 AM EDT - 11 days ago

Pfizer Announces Chief Financial Officer Transition

Jun 10, 2026, 7:56 AM EDT - 19 days ago

Pfizer CEO warns German investment at risk over drug pricing policies

2026-06-09T21:05:52.000Z - 19 days ago

Pfizer upgraded to Sector Perform from Underperform at RBC Capital

2026-06-09T21:05:12.000Z - 19 days ago

Pfizer upgraded to Sector Perform at RBC Capital amid more balanced risk-reward

Jun 9, 2026, 2:07 PM EDT - 20 days ago

Want to Avoid the Whipsawing Tech Stocks? Dollar General and 7 Others to Buy.

DG ALGN BBY BIIB CVS VZ

Jun 9, 2026, 9:20 AM EDT - 20 days ago

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

AMGN JNJ LLY MRK NVO

Jun 9, 2026, 3:20 AM EDT - 20 days ago

The space race is coming for pharma: Why drug development is heading to lower Earth orbit

BMY LLY MRK RDW UTHR XBI

Jun 8, 2026, 8:00 AM EDT - 21 days ago

Pfizer Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

2026-06-08T10:51:57.000Z - 21 days ago

Pfizer says FDA approves expanded indication for Hympavzi

Jun 8, 2026, 6:49 AM EDT - 21 days ago

US FDA approves Pfizer's bleeding disorder drug for children

Jun 8, 2026, 6:45 AM EDT - 21 days ago

U.S. FDA Approves Pfizer's HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need

2026-06-07T22:00:49.000Z - 21 days ago

Pfizer presents results from Phase 2b studies of berobenatide

Jun 6, 2026, 11:00 AM EDT - 23 days ago

Pfizer Transcript: Study update

Jun 6, 2026, 11:00 AM EDT - 23 days ago

Pfizer Slides: Study update

Jun 6, 2026, 11:00 AM EDT - 23 days ago

Pfizer Press release: Study update

Jun 6, 2026, 9:06 AM EDT - 23 days ago

Pfizer's monthly obesity shot has side-effect profile similar to Wegovy in midstage trial

Jun 6, 2026, 9:00 AM EDT - 23 days ago

Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer's GLP-1 RA Berobenatide

Jun 4, 2026, 10:00 AM EDT - 25 days ago

Chai Discovery Announces License Agreement with Pfizer to Accelerate Drug Discovery with AI

Jun 4, 2026, 6:40 AM EDT - 25 days ago

Why Pfizer And Eli Lilly Are Betting On This $1.3 Billion AI Drug Discovery Startup

LLY

Jun 3, 2026, 2:00 PM EDT - 26 days ago

Pfizer Transcript: Jefferies Global Healthcare Conference 2026

Jun 1, 2026, 10:00 AM EDT - 4 weeks ago

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

May 31, 2026, 8:00 AM EDT - 4 weeks ago

Pfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer

May 30, 2026, 9:22 AM EDT - 4 weeks ago

Mailbag: A Follow-Up on Pfizer & Other Questions

AGNC LAND NLY PFFA

May 30, 2026, 8:00 AM EDT - 4 weeks ago

TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer

May 29, 2026, 8:00 AM EDT - 4 weeks ago

Seven-Year Analysis from Pfizer's LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer

May 28, 2026, 11:10 PM EDT - 4 weeks ago

Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion

May 28, 2026, 7:19 PM EDT - 4 weeks ago

China's Innovent Biologics, Pfizer strike up to $10.5 billion cancer drug deal

May 28, 2026, 7:00 PM EDT - 4 weeks ago

Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines

May 28, 2026, 7:00 PM EDT - 4 weeks ago

Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines

May 27, 2026, 10:00 AM EDT - 4 weeks ago

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

May 20, 2026, 9:00 AM EDT - 5 weeks ago

Sarah Cannon Research Institute Announces Strategic Oncology Research Collaboration with Pfizer

May 20, 2026, 5:08 AM EDT - 5 weeks ago

Pfizer's pneumococcal shot shows stronger immune response in mid-stage trial

May 20, 2026, 5:05 AM EDT - 5 weeks ago

Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results

May 18, 2026, 8:00 AM EDT - 6 weeks ago

Astellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 2026

May 14, 2026, 2:22 PM EDT - 6 weeks ago

Quest Diagnostics, Altria, and 12 More Stocks That Are Coming Back to Life After a Rough Patch

DGX MO CL

May 13, 2026, 6:45 AM EDT - 6 weeks ago

European Commission Approves Pfizer's HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors

May 12, 2026, 8:00 AM EDT - 6 weeks ago

Rigel strikes licensing deal for Pfizer and Arvinas' breast cancer drug

ARVN RIGL

May 12, 2026, 7:00 AM EDT - 6 weeks ago

Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)

ARVN

May 5, 2026, 4:09 PM EDT - 7 weeks ago

Pfizer CEO on Drug Pipeline, Trump's Pick to Lead CDC

May 5, 2026, 4:02 PM EDT - 7 weeks ago

Pfizer CEO on AI-designed molecule, and race to use new tech

May 5, 2026, 11:30 AM EDT - 7 weeks ago

3 Dividend Stocks for May 2026

SYY WSO

May 5, 2026, 10:00 AM EDT - 7 weeks ago

Pfizer Earnings Call Transcript: Q1 2026

May 5, 2026, 10:00 AM EDT - 7 weeks ago

Pfizer Earnings release: Q1 2026

May 5, 2026, 10:00 AM EDT - 7 weeks ago

Pfizer Quarterly report: Q1 2026

May 5, 2026, 10:00 AM EDT - 7 weeks ago

Pfizer Slides: Q1 2026

May 5, 2026, 8:35 AM EDT - 7 weeks ago

Pfizer Posts Better-Than-Expected Revenue, Profit

May 5, 2026, 7:23 AM EDT - 7 weeks ago

Pfizer Revenue Rises But Profit Falls Amid Boosted R&D Spending

May 5, 2026, 7:06 AM EDT - 7 weeks ago

Pfizer Stock Edges Higher as Earnings and Revenue Beat Estimates

May 5, 2026, 7:05 AM EDT - 7 weeks ago

Why selling these 3 dividend stocks could be a mistake

EPD UPS

May 5, 2026, 6:55 AM EDT - 7 weeks ago

Pfizer tops Wall Street estimates, reaffirms outlook as newer products show growth

May 5, 2026, 6:51 AM EDT - 7 weeks ago

Pfizer beats first-quarter profit estimates on strong demand for blood thinner Eliquis

May 5, 2026, 6:45 AM EDT - 7 weeks ago

Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance

May 1, 2026, 12:37 PM EDT - 2 months ago

US FDA approves Pfizer, Arvinas' breast cancer drug

ARVN

woolybully Jun. 29 at 7:03 PM

$ELTP $WEN $GME $PFE $JNJ

1 · Reply

morgangj Jun. 29 at 6:58 PM

$PFE

0 · Reply

_Crim_Jamer_ Jun. 29 at 6:58 PM

$PFE gap near 26.

1 · Reply

Micheal_Pothead Jun. 29 at 6:14 PM

$PFE the most Pfizer shit ever

0 · Reply

Micheal_Pothead Jun. 29 at 6:13 PM

$PFE lmfao it can’t ever hold any gains

0 · Reply

sethmarcus Jun. 29 at 5:25 PM

$VIX $SPY $AMZN $MU $PFE

0 · Reply

LoneBroker Jun. 29 at 5:21 PM

0 · Reply

Micheal_Pothead Jun. 29 at 4:51 PM

$PFE hey LLY is green again :)

1 · Reply

PFElinepfrenzy1990 Jun. 29 at 4:50 PM

$PFE - Cursed Straße

0 · Reply

MrPeanutEsquire Jun. 29 at 4:44 PM

$PFE How about a little Pfizer trivia for our Monday. Over the last 5 years, what # do we rank on the s&p for performance?

3 · Reply

Micheal_Pothead Jun. 29 at 4:10 PM

$PFE I don’t think the market could be any more clear that it wants a new CEO

0 · Reply

SellasgpsCurativeBAT11 Jun. 29 at 3:43 PM

$PFE $SLS #1 Trending on Stocktwits WHY IT'S TRENDING SELLAS Life Sciences is surging as investors anticipate pivotal phase 3 clinical trial results, fueled by a high-pressure short squeeze environment and heavy institutional interest in its potential oncology breakthroughs. Community sentiment is overwhelmingly bullish, with active discussions focusing on the high cost to borrow shares, the scarcity of available short positions, and expectations for a major corporate catalyst. ✌️🙏❤️‍🩹

0 · Reply

kicker911 Jun. 29 at 3:38 PM

$PFE honestly seems way undervalued, safe and has a good dividend. Anything between 21-24 seems like a safe price on this stock.

0 · Reply

Micheal_Pothead Jun. 29 at 3:31 PM

$PFE buying doge coin when I bought PFE would have been a better investment…

1 · Reply

MrPeanutEsquire Jun. 29 at 3:25 PM

$PFE Just a little red. It could happen to anyone

1 · Reply

Micheal_Pothead Jun. 29 at 3:06 PM

$PFE genuinely what now

0 · Reply

Micheal_Pothead Jun. 29 at 3:03 PM

$PFE worthless

0 · Reply

saifnila2 Jun. 29 at 2:58 PM

$PFE what a terrible pos is boula. No insight, a fuking fool.

0 · Reply

SellasgpsCurativeBAT11 Jun. 29 at 2:33 PM

$SLS $PFE Pfizer has been making all the right moves in preparation of SLS BO since December 2025. Pfizer in January 2026 appointed Michael Burns brother of Sellas CFO John Burns as Senior Medical Director of Oncology Late Development, coming directly from oncology early development at AbbVie. Someone who spent their career in the belly of the beast understanding exactly how AbbVie develops oncology assets, exactly where the gaps in the Venetoclax franchise are, and exactly what kind of validated late stage asset Pfizer needs to compete in hematologic malignancies just walked through Pfizer's door. Pfizer didn't hire a hematology focused Chief Oncology Officer from Novartis and then bring in a Senior Medical Director of Late Development from AbbVie's oncology early development team by accident. That's a deliberate and coordinated build of expertise in precisely the space that Sellas GPS and 009 are about to disrupt. CEO Dr. Bourla and CEO Stergiou are friends. ✌️🙏❤️‍🩹

1 · Reply

SellasgpsCurativeBAT11 Jun. 29 at 2:28 PM

$ABBV $PFE $RVMD $SLS 10 Million Volume in first full hours of trading. Word of a CURATIVE cancer platform that can tackle 20+ WT1 cancers GPS is spreading on Wall Street just a few blocks away from Sellas Headquarters in N.Y ✌️🙏❤️‍🩹

0 · Reply

Micheal_Pothead Jun. 29 at 2:27 PM

$PFE 24.50

0 · Reply

SellasgpsCurativeBAT11 Jun. 29 at 2:21 PM

$ABBV $PFE $RVMD $SLS 0 Shares Available 👇 going to in to the biggest Catalyst in Sellas Corporate history with 63 Million short shares trapped. 👇 ✌️🙏❤️‍🩹

0 · Reply

Market Cap	138.44B
Revenue (ttm)	62.58B
Net Income (ttm)	7.77B
EPS (ttm)	N/A
PE Ratio	7.94
Forward PE	7.93
Profit Margin	12.42%
Debt to Equity Ratio	0.71

Volume	27,669,574
Avg Vol	39,788,496
Day's Range	N/A - N/A
Shares Out	5.70B
Stochastic %K	24%
Beta	0.34
Analysts	Sell
Price Target	$29.20